Acceleron Pharma 2016 Q4 Earnings Results

Acceleron Pharma presented its 4th quarter and full year 2016 financial and operational results on March 1, 2017. The company discussed progress on its drug pipeline including sotatercept, luspatercept, dalantercept, and ACE-083, as well as its IntelliTrap drug discovery platform and TGF-beta superfamily program. The presentation included updates on upcoming clinical milestones and regulatory timelines for ongoing development programs.